Advertisement

Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer

Abstract

Purpose

This study evaluated the efficacy and toxicity of combination chemotherapy with paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin (POFL) in patients with recurrent or metastatic gastric cancer.

Methods

One hundred and thirty-eight patients with histologically confirmed recurrent or metastatic gastric adenocarcinoma were treated with the POFL regimen: paclitaxel at a dose of 135 mg/m2 as a 3-hour intravenous infusion on day 1, oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 as an intravenous infusion over 2 hours on day 1, followed by 5-fluorouracil 2,400 mg/m2 as an infusion over a 46-hour period on 3 consecutive days, in a 2-week cycle.

Results

Twelve patients could not be evaluated for response because of the absence of any measurable lesions or early discontinuation of therapy, so responses were assessed in 126 patients. The overall objective response rate was 56.3% (95% CI, 47.5%-64.9%). The median time to progression was 6.7 months (95% CI, 5.8-7.6 months), and the median overall survival was 12.6 months (95% CI, 11.3-13.9 months). The most common grade 3 and 4 toxicities were neutropenia (50.7%), peripheral neurotoxicity (16.7%) and alopecia (27.5%).

Conclusions

Combination chemotherapy with POFL offers a new, active and safe approach to the treatment of recurrent or metastatic gastric cancer.

Post author correction

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/tj.5000665

Authors

Yan-qin Lan, Ri-ping Wu, Xiao-bing Huang, Xin-li Wang, Dong-ta Zhong, Chuan-yong Huang, Jin-tian Song

Article History

Disclosures

Financial support: The study was supported by the Foundation of Medical Innovation Project in Fujian Province (Grant No. 2016-CX-26).
Conflict of interest: None.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian - P.R. China
  • Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian - P.R. China
  • Fujian Medical University Stem Cell Research Institute, Fuzhou, Fujian - P.R. China
  • Department of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, Fujian - P.R. China
  • Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian - P.R. China
  • Yan-qin Lan and Chuan-yong Huang contributed equally to this work.

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.